Jianmin Pharmaceutical Group Co Ltd (600976) - Net Assets
Based on the latest financial reports, Jianmin Pharmaceutical Group Co Ltd (600976) has net assets worth CN¥2.77 Billion CNY (≈ $404.62 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.69 Billion ≈ $686.04 Million USD) and total liabilities (CN¥1.92 Billion ≈ $281.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Jianmin Pharmaceutical Group Co Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.77 Billion |
| % of Total Assets | 58.98% |
| Annual Growth Rate | 10.77% |
| 5-Year Change | 73.52% |
| 10-Year Change | 163.85% |
| Growth Volatility | 27.74 |
Jianmin Pharmaceutical Group Co Ltd - Net Assets Trend (2001–2025)
This chart illustrates how Jianmin Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. See Jianmin Pharmaceutical Group Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Jianmin Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual net assets of Jianmin Pharmaceutical Group Co Ltd from 2001 to 2025. For live valuation and market cap data, see Jianmin Pharmaceutical Group Co Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.72 Billion ≈ $398.20 Million |
+11.05% |
| 2024-12-31 | CN¥2.45 Billion ≈ $358.56 Million |
+8.59% |
| 2023-12-31 | CN¥2.26 Billion ≈ $330.19 Million |
+20.81% |
| 2022-12-31 | CN¥1.87 Billion ≈ $273.32 Million |
+19.10% |
| 2021-12-31 | CN¥1.57 Billion ≈ $229.48 Million |
+18.51% |
| 2020-12-31 | CN¥1.32 Billion ≈ $193.63 Million |
+9.55% |
| 2019-12-31 | CN¥1.21 Billion ≈ $176.76 Million |
+5.49% |
| 2018-12-31 | CN¥1.15 Billion ≈ $167.56 Million |
+3.40% |
| 2017-12-31 | CN¥1.11 Billion ≈ $162.05 Million |
+7.38% |
| 2016-12-31 | CN¥1.03 Billion ≈ $150.92 Million |
+3.41% |
| 2015-12-31 | CN¥997.36 Million ≈ $145.94 Million |
-0.47% |
| 2014-12-31 | CN¥1.00 Billion ≈ $146.63 Million |
+6.55% |
| 2013-12-31 | CN¥940.46 Million ≈ $137.62 Million |
+4.14% |
| 2012-12-31 | CN¥903.10 Million ≈ $132.15 Million |
+2.98% |
| 2011-12-31 | CN¥876.97 Million ≈ $128.33 Million |
+3.32% |
| 2010-12-31 | CN¥848.81 Million ≈ $124.21 Million |
+3.47% |
| 2009-12-31 | CN¥820.32 Million ≈ $120.04 Million |
+7.76% |
| 2008-12-31 | CN¥761.24 Million ≈ $111.39 Million |
+2.51% |
| 2007-12-31 | CN¥742.63 Million ≈ $108.67 Million |
-3.13% |
| 2006-12-31 | CN¥766.61 Million ≈ $112.18 Million |
+0.92% |
| 2005-12-31 | CN¥759.65 Million ≈ $111.16 Million |
+7.73% |
| 2004-12-31 | CN¥705.12 Million ≈ $103.18 Million |
+142.88% |
| 2003-12-31 | CN¥290.32 Million ≈ $42.48 Million |
+11.43% |
| 2002-12-31 | CN¥260.54 Million ≈ $38.12 Million |
+11.55% |
| 2001-12-31 | CN¥233.57 Million ≈ $34.18 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jianmin Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2346.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.83 Billion | 69.03% |
| Common Stock | CN¥153.40 Million | 5.77% |
| Other Comprehensive Income | CN¥167.30 Million | 6.30% |
| Other Components | CN¥502.06 Million | 18.90% |
| Total Equity | CN¥2.66 Billion | 100.00% |
Jianmin Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Jianmin Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hovnanian Enterprises Inc
NYSE:HOV
|
$632.90 Million |
|
Guangzhou Amsky Technology Co Ltd
SHE:300521
|
$632.99 Million |
|
Chongqing QinAn M&E PLC
SHG:603758
|
$633.11 Million |
|
Tongyang Inc
KO:001525
|
$633.38 Million |
|
Shinkong Textile Co Ltd
TW:1419
|
$632.59 Million |
|
EirGenix
TWO:6589
|
$632.48 Million |
|
APG SGA SA
SW:APGN
|
$632.38 Million |
|
Mrs. Bectors Food Specialities Limited
NSE:BECTORFOOD
|
$631.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jianmin Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,435,305,586 to 2,656,393,006, a change of 221,087,420 (9.1%).
- Net income of 359,841,141 contributed positively to equity growth.
- Dividend payments of 138,058,740 reduced retained earnings.
- Other comprehensive income decreased equity by 694,982.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥359.84 Million | +13.55% |
| Dividends Paid | CN¥138.06 Million | -5.2% |
| Other Comprehensive Income | CN¥-694.98K | -0.03% |
| Other Changes | CN¥1.00 | +0.0% |
| Total Change | CN¥- | 9.08% |
Book Value vs Market Value Analysis
This analysis compares Jianmin Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 20.26x to 1.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | CN¥1.39 | CN¥28.19 | x |
| 2002-12-31 | CN¥1.51 | CN¥28.19 | x |
| 2003-12-31 | CN¥1.46 | CN¥28.19 | x |
| 2004-12-31 | CN¥3.75 | CN¥28.19 | x |
| 2005-12-31 | CN¥3.86 | CN¥28.19 | x |
| 2006-12-31 | CN¥4.49 | CN¥28.19 | x |
| 2007-12-31 | CN¥4.30 | CN¥28.19 | x |
| 2008-12-31 | CN¥4.89 | CN¥28.19 | x |
| 2009-12-31 | CN¥5.09 | CN¥28.19 | x |
| 2010-12-31 | CN¥5.39 | CN¥28.19 | x |
| 2011-12-31 | CN¥5.56 | CN¥28.19 | x |
| 2012-12-31 | CN¥5.73 | CN¥28.19 | x |
| 2013-12-31 | CN¥6.00 | CN¥28.19 | x |
| 2014-12-31 | CN¥6.37 | CN¥28.19 | x |
| 2015-12-31 | CN¥6.42 | CN¥28.19 | x |
| 2016-12-31 | CN¥6.59 | CN¥28.19 | x |
| 2017-12-31 | CN¥7.08 | CN¥28.19 | x |
| 2018-12-31 | CN¥7.44 | CN¥28.19 | x |
| 2019-12-31 | CN¥7.88 | CN¥28.19 | x |
| 2020-12-31 | CN¥8.55 | CN¥28.19 | x |
| 2021-12-31 | CN¥10.28 | CN¥28.19 | x |
| 2022-12-31 | CN¥12.23 | CN¥28.19 | x |
| 2023-12-31 | CN¥14.70 | CN¥28.19 | x |
| 2024-12-31 | CN¥16.00 | CN¥28.19 | x |
| 2025-12-31 | CN¥17.32 | CN¥28.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jianmin Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.55%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.74%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 1.70x
- Recent ROE (13.55%) is above the historical average (9.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 9.93% | 7.59% | 0.72x | 1.83x | CN¥-142.79K |
| 2002 | 10.43% | 6.88% | 0.79x | 1.92x | CN¥1.03 Million |
| 2003 | 9.21% | 5.65% | 0.81x | 2.02x | CN¥-2.08 Million |
| 2004 | 4.14% | 5.28% | 0.57x | 1.37x | CN¥-39.56 Million |
| 2005 | 2.88% | 2.20% | 0.86x | 1.52x | CN¥-49.56 Million |
| 2006 | 1.63% | 0.89% | 1.23x | 1.50x | CN¥-58.85 Million |
| 2007 | 1.16% | 0.80% | 1.17x | 1.24x | CN¥-63.33 Million |
| 2008 | 2.15% | 1.89% | 0.72x | 1.58x | CN¥-57.62 Million |
| 2009 | 6.29% | 3.19% | 1.18x | 1.67x | CN¥-28.78 Million |
| 2010 | 8.72% | 4.56% | 1.46x | 1.31x | CN¥-10.48 Million |
| 2011 | 9.18% | 5.54% | 1.21x | 1.37x | CN¥-7.01 Million |
| 2012 | 9.42% | 5.35% | 1.22x | 1.44x | CN¥-5.09 Million |
| 2013 | 10.50% | 4.81% | 1.38x | 1.58x | CN¥4.60 Million |
| 2014 | 11.93% | 6.61% | 1.13x | 1.59x | CN¥18.80 Million |
| 2015 | 8.72% | 3.75% | 1.42x | 1.63x | CN¥-12.52 Million |
| 2016 | 6.38% | 2.74% | 1.31x | 1.78x | CN¥-36.76 Million |
| 2017 | 8.33% | 3.35% | 1.41x | 1.77x | CN¥-18.18 Million |
| 2018 | 7.13% | 3.76% | 1.26x | 1.51x | CN¥-32.76 Million |
| 2019 | 7.61% | 4.09% | 1.16x | 1.61x | CN¥-28.66 Million |
| 2020 | 11.22% | 6.02% | 1.02x | 1.84x | CN¥16.10 Million |
| 2021 | 19.55% | 9.25% | 1.17x | 1.81x | CN¥149.14 Million |
| 2022 | 21.91% | 11.21% | 1.06x | 1.85x | CN¥221.79 Million |
| 2023 | 23.20% | 12.38% | 1.01x | 1.85x | CN¥296.69 Million |
| 2024 | 14.87% | 10.33% | 0.82x | 1.76x | CN¥118.65 Million |
| 2025 | 13.55% | 10.74% | 0.74x | 1.70x | CN¥94.20 Million |
Industry Comparison
This section compares Jianmin Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,041,443,343
- Average return on equity (ROE) among peers: 10.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jianmin Pharmaceutical Group Co Ltd (600976) | CN¥2.77 Billion | 9.93% | 0.70x | $632.78 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $971.04 Million | 5.41% | 3.98x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.33 Billion | 6.10% | 1.68x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $8.39 Billion | 22.09% | 0.19x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $3.01 Billion | 11.93% | 0.53x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.15 Billion | 11.42% | 1.59x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $1.42 Billion | 23.64% | 1.01x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $445.29 Million | 14.73% | 0.90x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $347.80 Million | 3.58% | 0.72x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $905.53 Million | 2.15% | 1.95x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $3.00 Billion |
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells traditional Chinese medicines and paediatric products in China. It provides over-the-counter, medical, and general health products in the form of capsules, granules, and gels under the Jianmin, Longmu, and Yekaitai brands. The company was founded in 1637 and is based in Wuhan, China.